Switch to:
Also traded in: Germany, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 2.22
HCM's Cash-to-Debt is ranked higher than
50% of the 815 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. HCM: 2.22 )
Ranked among companies with meaningful Cash-to-Debt only.
HCM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.64  Med: 1.82 Max: 9.93
Current: 2.22
0.64
9.93
Equity-to-Asset 0.55
HCM's Equity-to-Asset is ranked lower than
63% of the 746 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. HCM: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
HCM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.54  Med: 0.46 Max: 0.77
Current: 0.55
-0.54
0.77
Piotroski F-Score: 4
Altman Z-Score: 10.35
Beneish M-Score: -2.03
WACC vs ROIC
12.22%
-17.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -10.43
HCM's Operating Margin % is ranked lower than
78% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. HCM: -10.43 )
Ranked among companies with meaningful Operating Margin % only.
HCM' s Operating Margin % Range Over the Past 10 Years
Min: -21.61  Med: -4.82 Max: 58.29
Current: -10.43
-21.61
58.29
Net Margin % 3.77
HCM's Net Margin % is ranked lower than
59% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.26 vs. HCM: 3.77 )
Ranked among companies with meaningful Net Margin % only.
HCM' s Net Margin % Range Over the Past 10 Years
Min: -26.4  Med: -2.34 Max: 16.27
Current: 3.77
-26.4
16.27
ROE % -17.94
HCM's ROE % is ranked lower than
79% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. HCM: -17.94 )
Ranked among companies with meaningful ROE % only.
HCM' s ROE % Range Over the Past 10 Years
Min: -57.96  Med: -11.5 Max: 9.22
Current: -17.94
-57.96
9.22
ROA % 2.62
HCM's ROA % is ranked lower than
55% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. HCM: 2.62 )
Ranked among companies with meaningful ROA % only.
HCM' s ROA % Range Over the Past 10 Years
Min: -16.75  Med: -1.69 Max: 4.38
Current: 2.62
-16.75
4.38
ROC (Joel Greenblatt) % -194.46
HCM's ROC (Joel Greenblatt) % is ranked lower than
85% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.97 vs. HCM: -194.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HCM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -471.68  Med: -17.31 Max: 193.62
Current: -194.46
-471.68
193.62
3-Year Revenue Growth Rate 75.90
HCM's 3-Year Revenue Growth Rate is ranked higher than
97% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. HCM: 75.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HCM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -41.8  Med: 24.5 Max: 100.1
Current: 75.9
-41.8
100.1
3-Year EPS without NRI Growth Rate 23.60
HCM's 3-Year EPS without NRI Growth Rate is ranked higher than
74% of the 580 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. HCM: 23.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HCM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -10  Med: 17.85 Max: 30.1
Current: 23.6
-10
30.1
GuruFocus has detected 4 Warning Signs with Hutchison China Meditech Ltd $HCM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HCM's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:OTCPK:GWPRF, NAS:AERI, OTCPK:BOIRF, OTCPK:HAWPF, OTCPK:MAYNF, AMEX:TXMD, OTCPK:VEGPF, NAS:RTRX, NAS:RMTI, OTCPK:ABSCF, NAS:ZGNX, NAS:NBRV, OTCPK:CKDXF, AMEX:NNVC, NAS:ALIM, NAS:OASM, NAS:PRPH, NAS:TNXP, OTCPK:CHEXD, NAS:IMNP » details
Traded in other countries:H7T.Germany, HCM.UK, HNCMF.USA,
Headquarter Location:Hong Kong
Hutchison China Meditech Ltd is a biopharmaceutical company. The Company along with its subsidiaries is engaged in researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.

Hutchison China Meditech Ltd is a major drug manufacturing company. The company operates two platforms--an innovation platform and a commercial platform. Hutchison's innovation platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases. The company's commercial platform includes the manufacturing, marketing, and distribution of prescription and over-the-counter pharmaceuticals in China as well as certain consumer products in Hong Kong. The vast majority of the company's revenue is generated through its commercial platform.

Top Ranked Articles about Hutchison China Meditech Ltd

Hutchison China Meditech Limited: Chi-Med to Announce 2016 HY Financial Results

HONG KONG, CHINA--(Marketwired - Jul 5, 2016) -  Hutchison China MediTech Limited (AIM: HCM) (NASDAQ: HCM) Chi-Med to Announce 2016 Half-Year Financial Results London: Tuesday, July 5, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2016 on Tuesday, August 2, 2016 at 7:00 am British Summer Time (BST). An analyst presentation will be held at 9:00 am BST (4:00 pm Hong Kong Time) on the same day at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY, UK, which will be webcast via the company website at www.chi-med.com/investors/event-information/. The presentation will be available to download before the analyst presentation begins. For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am Eastern Daylight Time (2:00 pm BST).  Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement. A replay will also be available on the website shortly after each event. NOTES TO EDITORS About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform, Hutchison MediPharma Limited, is focused on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. Its pipeline of eight novel oral compounds for cancer and inflammation is in development in North America, Europe, Australia and Greater China.  Chi-Med's Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com


Contacts
 
 
 
 


 
 
 
 
 


Investor Enquiries
 
 
 
 


Christian Hogg, CEO
 
852 2121 8200
 
 


International Media Enquiries
 
 
 
 


Anthony Carlisle, Citigate Dewe Rogerson
 
44 7973 611 888 (Mobile)
 
[email protected]


U.S. Based Media Enquiries
 
 
 
 


Brad Miles, BMC Communications
 
1 (917) 570 7340 (Mobile)
 
[email protected]


Susan Duffy, BMC Communications
 
1 (917) 499 8887 (Mobile)
 
[email protected]


Investor Relations
 
 
 
 


Jillian Connell, The Trout Group
 
1 (646) 378 2956
 
[email protected]


David Dible, Citigate Dewe Rogerson
 
44 7967 566 919 (Mobile)
 
[email protected]


Panmure Gordon (UK) Limited
 
 
 
 


Richard Gray / Andrew Potts
 
44 (20) 7886 2500
 
 





Contact:

RNS

Customer Services

0044-207797-4400

[email protected]

http://www.rns.com





Read more...

Ratios

vs
industry
vs
history
PE Ratio 3575.00
HCM's PE Ratio is ranked lower than
100% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.12 vs. HCM: 3575.00 )
Ranked among companies with meaningful PE Ratio only.
HCM' s PE Ratio Range Over the Past 10 Years
Min: 221.18  Med: 280.18 Max: 3575
Current: 3575
221.18
3575
PE Ratio without NRI 3575.00
HCM's PE Ratio without NRI is ranked lower than
100% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.32 vs. HCM: 3575.00 )
Ranked among companies with meaningful PE Ratio without NRI only.
HCM' s PE Ratio without NRI Range Over the Past 10 Years
Min: 219.55  Med: 278.12 Max: 3575
Current: 3575
219.55
3575
Price-to-Owner-Earnings 153.88
HCM's Price-to-Owner-Earnings is ranked lower than
90% of the 305 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.72 vs. HCM: 153.88 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HCM' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 104.73  Med: 167.74 Max: 2821.43
Current: 153.88
104.73
2821.43
PB Ratio 14.71
HCM's PB Ratio is ranked lower than
95% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. HCM: 14.71 )
Ranked among companies with meaningful PB Ratio only.
HCM' s PB Ratio Range Over the Past 10 Years
Min: 8.65  Med: 16.03 Max: 41.93
Current: 14.71
8.65
41.93
PS Ratio 62.28
HCM's PS Ratio is ranked lower than
94% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. HCM: 62.28 )
Ranked among companies with meaningful PS Ratio only.
HCM' s PS Ratio Range Over the Past 10 Years
Min: 9.38  Med: 16.95 Max: 62.28
Current: 62.28
9.38
62.28
Price-to-Free-Cash-Flow 458.33
HCM's Price-to-Free-Cash-Flow is ranked lower than
97% of the 210 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.65 vs. HCM: 458.33 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HCM' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 269.87  Med: 341.86 Max: 458.33
Current: 458.33
269.87
458.33
Price-to-Operating-Cash-Flow 425.60
HCM's Price-to-Operating-Cash-Flow is ranked lower than
98% of the 284 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.79 vs. HCM: 425.60 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HCM' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 250.6  Med: 317.44 Max: 425.6
Current: 425.6
250.6
425.6
EV-to-EBIT -158.02
HCM's EV-to-EBIT is ranked lower than
99.99% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.94 vs. HCM: -158.02 )
Ranked among companies with meaningful EV-to-EBIT only.
HCM' s EV-to-EBIT Range Over the Past 10 Years
Min: -269.7  Med: -76.7 Max: -39.3
Current: -158.02
-269.7
-39.3
EV-to-EBITDA -177.97
HCM's EV-to-EBITDA is ranked lower than
99.99% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.60 vs. HCM: -177.97 )
Ranked among companies with meaningful EV-to-EBITDA only.
HCM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -346.1  Med: -85.4 Max: -40.4
Current: -177.97
-346.1
-40.4
Current Ratio 1.76
HCM's Current Ratio is ranked lower than
65% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.44 vs. HCM: 1.76 )
Ranked among companies with meaningful Current Ratio only.
HCM' s Current Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.59 Max: 4.28
Current: 1.76
0.33
4.28
Quick Ratio 1.62
HCM's Quick Ratio is ranked lower than
55% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. HCM: 1.62 )
Ranked among companies with meaningful Quick Ratio only.
HCM' s Quick Ratio Range Over the Past 10 Years
Min: 0.23  Med: 1.24 Max: 3.87
Current: 1.62
0.23
3.87
Days Inventory 28.40
HCM's Days Inventory is ranked higher than
92% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.03 vs. HCM: 28.40 )
Ranked among companies with meaningful Days Inventory only.
HCM' s Days Inventory Range Over the Past 10 Years
Min: 17.86  Med: 127.27 Max: 448.99
Current: 28.4
17.86
448.99
Days Sales Outstanding 90.70
HCM's Days Sales Outstanding is ranked lower than
62% of the 655 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. HCM: 90.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
HCM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.75  Med: 68.62 Max: 155.16
Current: 90.7
26.75
155.16
Days Payable 103.78
HCM's Days Payable is ranked higher than
71% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.27 vs. HCM: 103.78 )
Ranked among companies with meaningful Days Payable only.
HCM' s Days Payable Range Over the Past 10 Years
Min: 53.45  Med: 69.98 Max: 103.78
Current: 103.78
53.45
103.78

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.30
HCM's 3-Year Average Share Buyback Ratio is ranked lower than
54% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. HCM: -5.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HCM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.8  Med: -0.5 Max: 0
Current: -5.3
-11.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 297.92
HCM's Price-to-Net-Current-Asset-Value is ranked lower than
99% of the 509 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. HCM: 297.92 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
HCM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.87  Med: 7.69 Max: 297.92
Current: 297.92
0.87
297.92
Price-to-Tangible-Book 15.00
HCM's Price-to-Tangible-Book is ranked lower than
90% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.51 vs. HCM: 15.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HCM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.45  Med: 5.99 Max: 33.29
Current: 15
0.45
33.29
Price-to-Intrinsic-Value-Projected-FCF 35.75
HCM's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
95% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. HCM: 35.75 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HCM' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 22.7  Med: 22.7 Max: 35.75
Current: 35.75
22.7
35.75
Price-to-Median-PS-Value 3.69
HCM's Price-to-Median-PS-Value is ranked lower than
94% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. HCM: 3.69 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HCM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 0.96 Max: 3.69
Current: 3.69
0.12
3.69
Earnings Yield (Greenblatt) % -0.63
HCM's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.98 vs. HCM: -0.63 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HCM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.5  Med: -1.3 Max: -0.4
Current: -0.63
-2.5
-0.4

More Statistics

Revenue (TTM) (Mil) $197.36
EPS (TTM) $ -0.01
Short Percentage of Float0.00%
52-Week Range $10.61 - 23.80
Shares Outstanding (Mil)121.43 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 231 296 322
EPS ($) -0.06 -0.20 0.19
EPS without NRI ($) -0.06 -0.20 0.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for HCM

Headlines

Articles On GuruFocus.com
Hutchison China Meditech Limited: Chi-Med to Announce 2016 HY Financial Results Jul 05 2016 
Hutchison China Meditech Limited: Savolitinib Global Phase II Trial Initiated Jun 20 2016 

More From Other Websites
Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China Jun 22 2017
Edison Issues ADR Update on Hutchison China MediTech (HCM) Jun 13 2017
Edison Issues Update on Hutchison China MediTech (HCM) Jun 13 2017
Chi-Med steps closer to Chinese pharma first with drug filing Jun 13 2017
Chi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer Jun 12 2017
Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO Jun 05 2017
Chi-Med Presents Clinical Data at ASCO 2017 Annual Meeting May 18 2017
Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for... Apr 07 2017
Chi-Med appoints Dr Weiguo Su, Chief Scientific Officer, to Board of Directors Mar 24 2017
Chi-Med To Host R&D Briefings on March 29 & 30, 2017 Mar 21 2017
Hutchison China MediTech Ltd. :HCM-US: Earnings Analysis: For the six months ended December 31, 2016... Mar 17 2017
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual... Mar 16 2017
Chi-Med: Grant of Awards under Long Term Incentive Plan Mar 16 2017
Publication of Annual Report and Financial Results for the Year Ended December 31, 2016 Mar 15 2017
Hutchison China Meditech Limited: Sulfatinib Phase Ib/II Results Presented at ENETS Mar 10 2017
Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference... Mar 10 2017
Billionaire Li's Biotech Firm a Step Closer to Putting New Cancer Drug on Market Mar 03 2017
Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of... Mar 03 2017
Hutchison China Meditech Limited: Positive Fruquintinib Pivotal Phase III Results Mar 03 2017
Hutchison China Meditech Limited: Change of Directors Feb 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}